Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H18BrN3O2 |
| Molecular Weight | 436.301 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
BrC1=CC=C(NC(=O)N2NC(=O)[C@H]([C@@H]2C3=CC=CC=C3)C4=CC=CC=C4)C=C1
InChI
InChIKey=LMUQHXHWJWQXSD-PMACEKPBSA-N
InChI=1S/C22H18BrN3O2/c23-17-11-13-18(14-12-17)24-22(28)26-20(16-9-5-2-6-10-16)19(21(27)25-26)15-7-3-1-4-8-15/h1-14,19-20H,(H,24,28)(H,25,27)/t19-,20-/m0/s1
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Subcutaneous administration of LY-288513 30 min before footshock (0.3 mg/kg) and 30 min before conditioned fear stress (0.03 mg/kg) reduced conditioned freezing in rats. https://www.ncbi.nlm.nih.gov/pubmed/8741161
Mice: In the elevated plus-maze, LY-288513 (3, 10 mg/kg, IP; 10, 30 mg/kg, PO) produced an anxiolytic-like action in mice with a magnitude of effect similar to that of diazepam. High doses of LY288513 (1000 mg/kg, PO) were required to reduce spontaneous activity levels, decrease body temperature, or potentiate the CNS-depressant effects of hexobarbital.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
147523-65-7
Created by
admin on Fri Dec 15 15:40:24 GMT 2023 , Edited by admin on Fri Dec 15 15:40:24 GMT 2023
|
PRIMARY | |||
|
2802894
Created by
admin on Fri Dec 15 15:40:24 GMT 2023 , Edited by admin on Fri Dec 15 15:40:24 GMT 2023
|
PRIMARY | |||
|
470GWP2CA0
Created by
admin on Fri Dec 15 15:40:24 GMT 2023 , Edited by admin on Fri Dec 15 15:40:24 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
